Stem cell · Conditions
What stem cells
actually treat.
Twelve indications across orthopedic, autoimmune, neurology, oncology and cosmetic — each graded by evidence quality. NMPA approval status flagged. Honest, sourced, free of marketing.
Twelve indications, graded
By evidence quality, not marketing.
Knee osteoarthritis
Autologous MSC intra-articular injection. Multiple Chinese RCTs show pain/function improvement vs HA. Best for grade I–III OA.
Graft-versus-host disease
Ruibosheng (amimestrocel) — China's first approved MSC drug — for steroid-refractory acute GVHD.
Rheumatoid arthritis
Allogeneic UC-MSC infusion. Adjunct to DMARDs in refractory active disease. Steroid-sparing.
Systemic lupus erythematosus
Allogeneic MSC immune modulation. Used in refractory active SLE; reduces disease activity scores.
Spinal cord injury
Intrathecal MSC + intensive PT in subacute phase. Modest motor improvement in selected patients.
Crohn's disease & IBD
Allogeneic MSC for refractory perianal fistulising Crohn's. Closure rates 50–60% in trials.
Type 2 diabetes
Allogeneic MSC infusion. HbA1c and C-peptide improvement in some refractory T2DM. Variable durability.
COPD & pulmonary fibrosis
MSC IV or inhaled exosomes. Small Chinese RCTs suggest functional improvement.
Chronic wound & burns
Topical or local-injection MSC + standard wound care. Faster healing in chronic non-healing wounds.
Post-stroke rehabilitation
Subacute MSC + intensive physiotherapy. Modest motor recovery beyond PT alone.
Parkinson's & neurodegenerative
iPSC-derived dopaminergic neurons in active trials. Not standard care. Trial enrollment for selected patients.
Hair loss (androgenic alopecia)
Exosome scalp injection + microneedling. Adjunct to minoxidil/finasteride. Cosmetic indication.
Evidence grades reflect aggregate quality of randomised trials and systematic reviews as of 2024. Only GVHD has formal NMPA approval (Ruibosheng); all other indications are off-label or trial-stage in China. Be wary of any clinic claiming ‘cure’ for chronic neurodegenerative or autoimmune disease — it does not exist.
FAQ
Conditions, in plain language.
- What conditions does stem cell therapy treat best?
- Strongest evidence: knee osteoarthritis (multiple Chinese RCTs vs hyaluronic acid), graft-versus-host disease (NMPA-approved indication via Ruibosheng), and chronic wound healing. Moderate evidence: rheumatoid arthritis and SLE (immune modulation in refractory cases), spinal cord injury (subacute motor recovery adjunct). Emerging: type 2 diabetes (β-cell support), COPD, and neurodegenerative disease. The honest answer: evidence is strongest for orthopedic OA and GVHD; weaker but promising for systemic inflammatory and degenerative conditions.
- Can stem cells cure autoimmune disease?
- Cure — no. Modulate — yes, in some cases. Allogeneic MSC infusion shows immune modulation in refractory rheumatoid arthritis, SLE, and Crohn's disease. Chinese RCTs suggest reduced disease activity scores and steroid-sparing benefit in selected refractory patients. Used as adjunct to DMARDs / biologics — not as a replacement. Discuss honestly with your rheumatologist.
- Will stem cells regenerate cartilage in my knee?
- Partially. Autologous MSC injected intra-articularly into an osteoarthritic knee produces measurable pain and function improvement vs hyaluronic acid in multiple Chinese trials. The mechanism is partly anti-inflammatory and partly limited cartilage regeneration. It does not restore advanced grade-IV cartilage loss to grade-0. Best for early-to-moderate OA before arthroplasty becomes necessary, or post-arthroscopic cartilage repair augmentation.
- What about Parkinson's, Alzheimer's, and ALS?
- Investigational only. iPSC-derived dopaminergic neurons for Parkinson's are in active Chinese trials with promising early data; not standard care. MSC infusion for Alzheimer's and ALS shows modest cognitive/functional support in some small trials but is not curative. Be wary of any clinic claiming Parkinson's or Alzheimer's 'cure' via stem cells — it does not exist. Trial enrollment may be appropriate for selected patients.
- Can stem cells help post-stroke recovery?
- Adjunct to physiotherapy. Chinese trials show intrathecal MSC + intensive rehabilitation in subacute stroke phase improves motor recovery beyond physiotherapy alone in selected patients. Effect is modest, not transformative. Best initiated 2–6 months post-stroke. Not a substitute for tPA, mechanical thrombectomy, or comprehensive stroke unit care in acute phase.
- Stem cell therapy for type 2 diabetes — does it work?
- Mixed evidence. Allogeneic MSC infusion can reduce HbA1c and increase C-peptide in some refractory T2DM patients, particularly with longer disease duration and failing oral therapy. Effect durability is variable — some patients sustain improvement 12–24 months, others regress. Not a cure. Used as adjunct to standard diabetes management.
Honest candidacy
review, free.
Submit your records. A 30-minute video review with a senior physician will tell you straight whether stem cell therapy can help your specific condition — and what realistic outcomes look like.